Date & Time
April 18, 12:00 PM ET / 9:00 AM PT
Webinar Details provided upon RSVP Approval
About the Event
MAIA Biotechnology (NYSE: MAIA) has developed THIO, a new platform of telomere-targeting agents that attack cancer tumors in a whole new way. It kills 70-90% of the cancer cells in just 24-72 hours and when used with a checkpoint inhibitor leads to complete response and no recurrence.
The company recently announced positive topline data from the completed Part A safety lead-in of their THIO-101 Phase 2 go-to-market trial in advanced Non-Small Cell Lung Cancer (NSCLC) and has commenced recruitment in Part B randomized efficacy/dose selection.
Join our webinar with MAIA CEO, Vlad Vitoc, to hear about the company’s Phase 2 clinical trials and why the FDA has awarded the platform two Orphan Drug Designations.